Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Gilead Sciences Inc. closed $3.98 short of its 52-week high ($87.87), which the company achieved on January 19th.

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other biotech stocks. As we have mentioned in our article, “10 Best Penny Stocks to ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $74.00. The company’s shares closed yesterday at $79.70.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences reported good quarterly results and in the last few weeks, the stock rallied higher. Oncology will especially contribute to growth in the years to come, and maybe Gilead Sciences ...

Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to their trading decisions The top 15 shareholders own 50% of the company Ownership research ...

Two years after the St George’s High School was destroyed by a fire, the school was rebuilt and renamed the St George’s School of Sciences. Minister of Education Priya Manickchand on Monday visited ...

The best free logo maker lets you create eye-catching graphics to market your business completely free. Our team of creatives tested out the best logo makers and the best graphic design software ...

Since my last article, Gilead Sciences, Inc.'s stock price has continued to rise, thanks in part to strong sales of its HIV portfolio and an improved EBIT margin year-over-year. So, sales of the ...